-
Mavenclad Quickly Reduces MRI Lesions in Early MS, ORACLE-MS Data Show
Phase 3 trial data show CIS patients on Mavenclad within 13 weeks had a lower lesion number and volume, and a lesser risk of MS onset. Click here to read more.
Do these findings surprise you? Why or why not?
Sorry, there were no replies found.
Log in to reply.